MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. reported strong first quarter 2026 results with broad-based growth. Net income rose 30% to $1.14 billion, or $1.74 per share, while adjusted earnings increased 18% to $1.59 billion, or $2.42 per share, driven by higher variable investment income, volume growth and favorable underwriting.
Premiums, fees and other revenues grew 5% to $14.3 billion, and net investment income increased 10% to $5.36 billion. Segments delivered double‑digit adjusted earnings growth in Group Benefits, Retirement and Income Solutions, Asia, EMEA and MetLife Investment Management. Return on equity reached 18.2%, with adjusted ROE at 17.0%. MetLife returned over $1.1 billion to shareholders via dividends and buybacks, while book value per share rose to $37.92 and adjusted book value per share to $57.41.
MetLife submitted a Form 144 reporting proposed sales of Common Stock through Barclays. The filing lists recent transactions by plan/accounts, with sample dispositions including 725 shares on 03/02/2026 and 145 shares on 03/20/2026. The filing date shown is 05/05/2026.
MetLife Inc. EVP & Chief Accounting Officer Adrienne Karen O'Neill received a grant of 12,485 shares of Common Stock on April 30, 2026. The award is described as a restricted stock unit grant under the MetLife, Inc. 2025 Stock and Incentive Compensation Plan. Following this compensation-related acquisition, she directly holds 27,042 shares.
MetLife Inc ownership filing shows Vanguard Capital Management beneficially owns 41,496,623 shares of Common Stock, representing 6.36% of the class as reported 03/31/2026. The filing states Vanguard has sole dispositive power over 41,496,623 shares and sole voting power for 5,639,806 shares.
MetLife, Inc. is asking shareholders to vote at its virtual-only 2026 annual meeting on three items: electing 11 directors for one-year terms, ratifying Deloitte & Touche LLP as auditor for 2026, and approving on an advisory basis executive compensation.
The proxy highlights the second year of MetLife’s five-year New Frontier strategy, targeting double-digit adjusted EPS growth, 15–17% adjusted ROE, a 100 basis point reduction in the direct expense ratio from 12.3%, and more than $25 billion in free cash flow over 2025–2029. In 2025, net income available to common shareholders was $3,173 million or $4.71 per diluted share, compared with $4,226 million or $5.94 in 2024, while ROE was 12.9% versus 16.9%.
The filing describes strong pay‑for‑performance alignment, with most 2025 total compensation for named executive officers variable and 70% of stock-based long‑term incentives tied to relative total shareholder return and adjusted ROE. It also details board refreshment, governance practices, risk and cybersecurity oversight, and a fully independent board chair structure.
MetLife, Inc. is providing preliminary information on its variable investment income for the quarter ended March 31, 2026 ahead of its full quarterly results. The company estimates pre-tax variable investment income of $475 million to $525 million, compared with full-year 2026 guidance of approximately $1.6 billion pre-tax.
Variable investment income reflects results from private equity, real estate and other funds, as well as prepayment fees. The figures are unaudited, based on preliminary data, and may differ materially once financial closing procedures are complete. MetLife emphasizes that this information is not a substitute for U.S. GAAP financial statements and includes forward-looking statements subject to risk factors described in its SEC filings.
Harris Carla A reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carla A. Harris received an award of 721 shares of common stock as part of non-management director compensation. The shares were valued at $71.17 each and are being deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, Harris directly holds 10,485 shares of MetLife common stock.
Seitz Michelle reported acquisition or exercise transactions in this Form 4 filing.
METLIFE INC director Michelle Seitz received a grant of 721 shares of Common Stock as part of her board compensation. The shares were awarded at a stated price of $0.00 per share as a non-management director retainer paid in MetLife common stock. Following this award, she holds 994 shares directly.
Kennard William E reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director William E. Kennard received a grant of 721 shares of MetLife common stock on April 1, 2026, as part of non‑management director compensation. The shares were valued at $71.17 each and he elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this award, Kennard is reported as beneficially owning 46,501 shares of MetLife common stock directly, and an additional 10 shares are held indirectly in the MetLife Policyholder Trust that holds stock allocated to eligible policyholders.